Immunohistochemical labeling of cone photoreceptor cells from a human retina.
Image courtesy of Robert Mullins, PhD, University of Iowa.
Millions of people with serious eye diseases suffer the devastating impact of vision loss on their ability to perform the tasks we take for granted. With no effective treatments available, reading, driving and recognizing faces can become impossible, and independence is lost.
Imagen Biotech, Inc. is a private, venture-backed biopharmaceutical company dedicated to identifying and developing therapeutics for sight-threatening diseases with high unmet medical needs, including dry age-related macular degeneration (dry AMD) which afflicts an estimated 13 million people.
Imagen's leadership has a proven track record for advancing revolutionary new treatments for blinding diseases. At Eyetech Pharmaceuticals they helped transform the lives of millions of patients with wet age-related macular degeneration (wet AMD) by ushering in the new era of VEGF-targeted drug therapy to preserve vision.
Now at Imagen, and supported by three leading investor groups with significant capabilities and investments in the ophthalmology space, they are directing their specialized ophthalmology industry experience, expertise and network to developing breakthrough therapies for historically untreatable diseases.
Through our global research and pharmaceutical network, Imagen is screening numerous compounds to determine their feasibility as drug development candidates.
We continue to seek collaborations worldwide with companies, institutions and researchers who have identified new pathways and/or compounds that might lead to a treatment for sight-threatening diseases, whether prevalent or rare.
If you have a promising technology that may be applicable to serious ophthalmology diseases with unmet medical needs, we look forward to learning more.
Together, we can help give people a new vision for life.